FKONCO

DSP Merrill Lynch Limited has submitted to the Exchange a copy of Exit offer Public Announcement made by Fresenius Kabi (Singapore) Pte Ltd to the public shareholders of Fresenius Kabi Oncology Limited ("company") ("Delisting Offer").

Fresenius Kabi Oncology Limited has informed the Exchange that with reference to the earlier letter dated October 18, 2013, informing about the Securities Appellate Tribunal's (SAT) order dated October 18, 2013, granting the Company an extension of 2 months from October 22, 2013 for completing the Delisting Offer, Fresenius Kabi Oncology Ltd has now informed that the Company has on October 21, 2013 has received the copy of aforementioned SAT order dated October 18, 2013.

Fresenius Kabi Oncology Limited had informed the Exchange regarding the delisting update dated October 14, 2013. The Company has now informed the Exchange that the Company had filed a Miscellaneous Application No. 113 of 2013 in Appeal No. 133 of 2013 before the Hon'ble Securities Appellate Tribunal (SAT) seeking an extension of time to complete the Delisting Offer. The Hon'ble SAT disposed off the SAT Application on October 18, 2013. An order was passed in the open court granting the Company an extension of 2 months from October 22, 2013 for completing the Delisting Offer.

Fresenius Kabi Oncology Limited had informed the Exchange regarding the delisting update dated October 12, 2013. The Company has now informed that Securities and Exchange Board of India (SEBI), vide its letter dated October 14, 2013, has advised the Company to approach Securities Appellate Tribunal (SAT) for seeking any relief including extension of time.

Fresenius Kabi Oncology Limited has informed the Exchange that the promoter of the Company i.e. Fresenius Kabi (Singapore) Pte Ltd. ("FKSL ) has informed that in terms of paragraph 20.1 of the public announcement dated September 16, 2013 ("PA ) and the corresponding letters of offer ("Letter of Offer ) despatched to the public shareholders of the Company, the acquisition of shares of the Company by FKSL pursuant to the delisting offer is subject to the decision of the Securities and Exchange Board of India ( SEBI ) on the application dated September 12, 2013 filed by the Company seeking an ext

Fresenius Kabi Oncology Limited has informed the Exchange that Hon'ble Securities Appellate Tribunal, Mumbai (SAT), vide its order dated September 10, 2013, has allowed the appeal filled by the Company against order dated July 22, 2013 passed by the Securities and Exchange Board of India (SEBI) to extent that the Company may go ahead with the delisting offer without the condition imposed by Securities and Exchange Board of India (SEBI) regarding compliance with Regulation 17(b) of SEBI (Delisting of Equity Shares) Regulations, 2009.

Fresenius Kabi Oncology Limited has informed the Exchange that with reference to the earlier announcement dated February 26, 2013 regarding US FDA inspection resulting in putting on hold the production at Company's API plant located at Kalyani, District Nadia, West Bengal, (India) and subsequent warning letter dated July 01, 2013, asking for certain other information and implementation of more corrective and preventive measures so as to avoid recurrence of deviations. In view of the observation made by US FDA, the Company had initiated necessary corrective and preventive steps for improving qu

Fresenius Kabi Oncology Limited has informed the Exchange that the Company had filed an appeal (no. 133 of 2013) before Hon'ble Securities Appellate Tribunal, Mumbai (SAT) against the directions contained in paragraph 13(ii) of order no. WTM/PS/16/CFD/JULY/2013, dated July 22, 2013 passed by the Securities and Exchange Board of India (SEBI). In this regard, the Company has submitted to the Exchange a copy of the SAT order dated August 01, 2013.

Fresenius Kabi Oncology Limited has informed the Exchange that with reference to the earlier announcement dated February 26, 2013, regarding putting on hold the production at Company's API plant located at Kalyani, District Nadia, West Bengal, (India) in view of certain observations made by US FDA in respect of manufacturing, documentation practices and product testing during a routine inspection. The Company has now informed the Exchange that the Company has received a warning letter from US FDA, inter-alia, asking for certain other information and implementation of more corrective and preven

Fresenius Kabi Oncology Limited has informed the Exchange that: "On June 04, 2013, the Hon'ble Whole Time Member of the Securities and Exchange Board of India ("SEBI") passed an interim order (Ref no: WTM/PS/08/CFD/JUNE/2013) ("Order") - (a) directing the freezing of voting rights and corporate benefits with respect to the excess of proportionate promoter shareholding in the Company, till such time that the Company complies with the minimum public shareholding ("MPS") norms; (b) prohibiting the promoter of the Company and directors of the Company from buying, selling or otherwise dealing in se

Fresenius Kabi Oncology Limited has informed the Exchange that "With reference to earlier announcement dated April 17, 2013, the Company has received a letter dated April 16, 2013 ("Letter") from Fresenius Kabi (Singapore) Pte Ltd, the promoter shareholder of the Company ("FKSL") notifying the Company of its intention to make a voluntary delisting offer to the public shareholders of the Company ("Delisting Offer") to acquire the entire public shareholding of the Company (i.e. 3,00,63,255 equity shares of Re. 1 each, representing 19% of the share capital of the Company) and delist the equity sh

Fresenius Kabi Oncology Limited has informed the Exchange that during a recent routine US FDA inspection at Company's API plant located at Kalyani, District Nadia, West Bengal, (India), US FDA made certain observations relating to GMP non-conformities in respect of manufacturing, documentation practices and product testing. However, all finished products conform to approved standards and specifications. The Company has immediately taken steps to implement remedial measures and has voluntarily put the production on hold. The Company's dosage form plants in Himachal Pradesh continue normal produ

Fresenius Kabi Oncology Limited has informed the Exchange that the Company has received a letter dated May 30, 2012 from its promoter shareholder, Fresenius Kabi (Singapore) Pte Ltd. ("FKSL").

Fresenius Kabi Oncology Limited had informed the Exchange regarding disinvestment of Fresenius Kabi Oncology Ltd's entire shareholding in Fresenius Kabi Oncology Plc, UK to Fresenius Kabi, Germany and its affiliates. The Company has now informed the Exchange that the Company has finalized and executed the share purchase agreement with Fresenius Kabi AG w.e.f. June 24, 2011.In terms of the aforesaid share purchase agreement, Company's entire shareholding of 171400000 equity shares of GBP 0.10 each in Fresenius Kabi Oncology Plc, UK now stands transferred to Fresenius Kabi AG (Germany) at the bo

Fresenius Kabi Oncology Limited has informed the Exchange that Dabur Pharma (Thailand) Co. Ltd, the wholly owned subsidiary of Fresenius Kabi Oncology Limited in Thailand, has been dissolved w.e.f. January 14, 2011 as per the applicable laws in Thailand.

Fresenius Kabi Oncology Limited has informed the Exchange that the Board of Directors of the Company in its meeting held on July 29, 2010, inter alia, took note of the following : (1) Dissolution of Fresenius Kabi Oncology Inc. (USA), the Indirect Wholly Owned Subsidiary in USA w.e.f. March 24, 2010.

Fresenius Kabi Oncology Limited has informed the Exchange that with a view to integrate its operations in Thailand, the Board of Directors of Fresenius Kabi Oncology Limited has on February 22, 2010 accorded its approval for: (1) Subject to compliance of applicable laws in Thailand, transfer the entire business, including all assets and liabilities of its wholly owned subsidiary in Thailand i.e. Dabur Pharma (Thailand) Company Limited at Fresenius Kabi (Thailand) Limited at the book value. (2) Subsequently dissolve/liquidate Dabur Pharma (Thailand) Company Ltd. as per the applicable laws in Th

Dabur Pharma Limited has informed the Exchange that UK's Medicines and Healthcare products Regulatory Agency (MHRA) Licensing Authority has granted the marketing authorization for Bicalutamide 50mg tablet to the Company.

Dabur Pharma Limited has informed the Exchange regarding cancellation/ option to surrender the Stock Options. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Dabur_UPDATE_05082008.zip target=NEW> For more details click here.</a>

Dabur Pharma Limited has informed the Exchange vide its letter dated April 18, 2008 that "at the meeting of the Board of Directors of Dabur Pharma Limited ("Company") held today, the Board has, subject to the approval of the shareholders and other necessary statutory and regulatory approvals, approved the following: 1) the cancellation of 1,481,226 outstanding employee stock options granted to certain employees of the Company. 2) Providing an option to the other employees of the Company to surrender their outstanding stock options/ shadow options, in consideration of cash compensation of Rs. 9